不同分子分型乳腺癌中的K-ras基因突变检测及其意义

Detection of K-ras gene mutation in breast cancer with different molecular types and its significance

目的了解K-ras基因在不同分子分型乳腺癌组织内的突变情况,为临床应用西妥昔单抗治疗乳腺癌提供理论支持。方法使用免疫组化方法检测50例乳腺癌组织内ER、PR、HER-2、Ki-67表达情况,并进行分子分型;同时提取石蜡组织DNA,利用ARMS实时荧光定量PCR法,检测乳腺癌样本中是否存在K-ras基因第12、13密码子突变以及突变的种类。结果本实验所选50例乳腺癌组织,按分子分型分为:Luminal A型12例,Luminal B型21例,HER2阳性型8例,三阴性乳腺癌9例。均未检测到K-ras基因突变,第12、13密码子均为野生型。结论K-ras基因在人乳腺癌组织中的突变率极低,乳腺癌患者有可能从西妥昔单抗单用或联合其他药物等综合治疗中获益。

Objective To understand the mutation of K-ras gene in breast cancer tissues with different molecular types, and to provide theoretical support for clinical application of cetuximab in the treatment of breast cancer. Methods Immunohistochemical method was used to detect the expression of ER, PR, HER-2, Ki-67 in 50 breast cancer tissues, and molecular typing was performed. At the same time, paraffin tissue DNA was extracted and ARMS real-time quantitative PCR was used to detect breast cancer samples Whether there are mutations in codons 12 and 13 of the K-ras gene and the types of mutations. Results No mutations in the Kras gene were detected in the selected cases, all of which were wild type. Conclusion The mutation rate of Kras gene in human breast cancer tissues is extremely low. Breast cancer patients may benefit from the combined treatment of cetuximab alone or in combination with other drugs.